



| <u>Procedure</u> | <u>Result</u> | <u>Units</u> | <u>Ref Interval</u> | <u>Accession</u> | <u>Collected</u> | <u>Received</u> | <u>Reported/</u> <u>Verified</u> |
|--------------------|---------------|--------------|---------------------|------------------|------------------|-----------------|---|
| Leukotriene, Urine | 309 Hf@ | | [<=104] | 19-345-900081 | 11-Dec-19 | 11-Dec-19 | 11-Dec-19 12:03:00 16:25:00 15:29:54 |

11-Dec-19 12:03:00 Leukotriene, Urine:
 Leukotriene E(4) (LTE4) > 104 pg/mg creatinine is consistent with the diagnosis of systemic mast cell disease, in adults. The clinical sensitivity of LTE4 is 48% in patients with systemic mastocytosis. When LTE4 concentrations are combined with other biochemical markers of mast cell activation, N-methyl histamine (NMH) and 2,3-dinor 11-Beta Prostaglandin F(2) Alpha (2,3BPG), the clinical sensitivity increases to 92%. Results should be interpreted in the context of the patient's clinical condition.

-----ADDITIONAL INFORMATION-----

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
 Test Performed by:
 Mayo Clinic Laboratories - Rochester Main Campus
 200 First Street SW, Rochester, MN 55905
 Lab Director: William G. Morice M.D. Ph.D.; CLIA# 24D0404292
 11-Dec-19 12:03:00 Leukotriene, Urine:

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab